Compare Dishman Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ABBOTT INDIA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ABBOTT INDIA DISHMAN PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 25.1 54.2 46.3% View Chart
P/BV x 3.3 13.1 25.6% View Chart
Dividend Yield % 0.7 0.5 126.4%  

Financials

 DISHMAN PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ABBOTT INDIA
Mar-19
DISHMAN PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs3748,834 4.2%   
Low Rs1295,458 2.4%   
Sales per share (Unadj.) Rs197.81,731.1 11.4%  
Earnings per share (Unadj.) Rs21.2211.9 10.0%  
Cash flow per share (Unadj.) Rs34.7219.9 15.8%  
Dividends per share (Unadj.) Rs2.0065.00 3.1%  
Dividend yield (eoy) %0.80.9 87.4%  
Book value per share (Unadj.) Rs179.9945.2 19.0%  
Shares outstanding (eoy) m80.6921.25 379.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.1 30.8%   
Avg P/E ratio x11.933.7 35.2%  
P/CF ratio (eoy) x7.232.5 22.3%  
Price / Book Value ratio x1.47.6 18.5%  
Dividend payout %9.430.7 30.7%   
Avg Mkt Cap Rs m20,306151,848 13.4%   
No. of employees `0000.83.5 23.8%   
Total wages/salary Rs m5,3554,356 122.9%   
Avg. sales/employee Rs Th19,252.710,555.5 182.4%   
Avg. wages/employee Rs Th6,459.51,249.9 516.8%   
Avg. net profit/employee Rs Th2,064.11,292.2 159.7%   
INCOME DATA
Net Sales Rs m15,96136,786 43.4%  
Other income Rs m2651,133 23.4%   
Total revenues Rs m16,22637,919 42.8%   
Gross profit Rs m4,1036,047 67.9%  
Depreciation Rs m1,091169 644.6%   
Interest Rs m94423 4,197.3%   
Profit before tax Rs m2,3346,989 33.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,485 25.1%   
Profit after tax Rs m1,7114,503 38.0%  
Gross profit margin %25.716.4 156.4%  
Effective tax rate %26.735.6 75.1%   
Net profit margin %10.712.2 87.6%  
BALANCE SHEET DATA
Current assets Rs m11,01827,610 39.9%   
Current liabilities Rs m9,5178,569 111.1%   
Net working cap to sales %9.451.8 18.2%  
Current ratio x1.23.2 35.9%  
Inventory Days Days11060 183.5%  
Debtors Days Days3527 127.2%  
Net fixed assets Rs m16,3041,057 1,542.6%   
Share capital Rs m161213 76.0%   
"Free" reserves Rs m12,90719,873 64.9%   
Net worth Rs m14,51620,086 72.3%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80529,409 101.3%  
Interest coverage x3.5311.6 1.1%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.3 42.8%   
Return on assets %8.915.4 57.9%  
Return on equity %11.822.4 52.6%  
Return on capital %17.534.9 50.2%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,952369 1,342.0%   
Fx outflow Rs m6974,918 14.2%   
Net fx Rs m4,255-4,549 -93.5%   
CASH FLOW
From Operations Rs m2,7864,991 55.8%  
From Investments Rs m-1,529-2,570 59.5%  
From Financial Activity Rs m-941-1,428 65.9%  
Net Cashflow Rs m316993 31.9%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 7.9 46.8%  
FIIs % 12.7 0.1 12,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.1 129.2%  
Shareholders   46,261 18,270 253.2%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - STRIDES PHARMA SCIENCE COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS